Kamal, Natasha
,
Koh, Christopher
Samala, Niharika
Fontana, Robert J.
Stolz, Andrew
Durazo, Francisco
Hayashi, Paul H.
Phillips, Elizabeth
Wang, Tongrong
Hoofnagle, Jay H.
Funding for this research was provided by:
NIDDK (2U01-DK065179-06, 2U01-DK065201-06, 2U01-DK065184-06, 2U01-DK065211-06, 1U01-DK083020-01)
Article History
Received: 12 April 2019
Accepted: 5 July 2019
First Online: 7 August 2019
Compliance with ethical standards
:
: Natasha Kamal has nothing to disclose. Christopher Koh has nothing to disclose. Niharika Samala has nothing to disclose. Andrew Stolz has nothing to disclose. Paul H. Hayashi has nothing to disclose. Tongrong Wang has nothing to disclose. Jay H. Hoofnagle has nothing to disclose. Francisco Durazo receives consulting fees from Intercept Pharmaceuticals. Robert J. Fontana receives grant support from Abbvie, Gilead Sciences and Bristol-Myers-Squibb and consulting fees from Sanofi-Aventis. Elizabeth Phillips receives personal fees from UpToDate and Biocryst and holds patent for HLA-B*57:01 testing for abacavir hypersensitivity without financial remuneration.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. The DILIN Prospective Study was approved by the Institutional Review Boards of the enrolling clinical centers, and all participants provided written informed consent.